Stem Cell Priming Composition for Immunomodulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current immunosuppressive and anti-inflammatory agents have significant side effects and low long-term efficacy in clinical trials, necessitating the development of safer and more effective therapies for inflammatory and immune diseases, particularly in stem cell treatments where persistence of effects and survival rates are concerns.

Innovation Solution

A composition comprising TNF-α, IFN-γ, and IFN-α, with optional vitamins such as vitamin B2, vitamin B3, or vitamin B6, is used to enhance the immunomodulatory and inflammation-modulating abilities of stem cells, improving their therapeutic potential by upregulating expression of immunoregulatory factors like IDO and TSG6.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional immunosuppressive agents (cyclosporine, azathioprine, prednisolone) are used to suppress inflammation and immune responses, then immunosuppression effect is achieved, but side effects such as nephrotoxicity, hepatotoxicity, bone marrow suppression, and other toxicities occur

Engineering Contradiction:

Improveimmunosuppression effectVSAvoidside effects (nephrotoxicity, hepatotoxicity, bone marrow suppression)

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses stem cells as an intermediary biological agent to mediate immunosuppression and anti-inflammatory effects. Instead of directly administering drugs that suppress immune function, stem cells are introduced to indirectly modulate the immune response through paracrine mechanisms, cell-cell interactions, and immunomodulatory factor secretion, thereby achieving therapeutic effects while avoiding direct drug toxicity

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mechanical/pharmacological approach of direct drug administration with a biological approach using living stem cells. The therapeutic mechanism shifts from direct drug-receptor interactions to complex biological processes including stem cell differentiation, immune cell modulation, and tissue regeneration, thereby reducing harmful side effects

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Object-affected harmful factors

If stem cells are used for therapy to avoid drug side effects, then safety is improved, but persistence of effects and in vitro survival rates are extremely low

Engineering Contradiction:

Improvedrug side effectsVSAvoidpersistence of effects and survival rate

Core Design Contradiction:

Object-affected harmful factorsVSDuration of action of stationary object

Solution Approach 1:

The patent applies preliminary culture and pre-conditioning of stem cells before transplantation to enhance their therapeutic efficacy and survival capabilities. Stem cells are cultured under specific conditions that prime them for improved engraftment, persistence, and functional activity in the target tissue, thereby addressing the low survival rate and short duration of action

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent optimizes various cultural and biological parameters including oxygen tension, growth factors, and culture medium composition to enhance stem cell survival and persistence. By adjusting these parameters during culture and transplantation, the therapeutic duration and effectiveness are significantly improved while maintaining safety

Inventive Principle:

Principle #35Parameter changes

3Reliability

If genetic manipulation is used to reinforce stem cell functions, then therapeutic effect is increased, but safety concerns arise from introduced genes

Engineering Contradiction:

Improvetherapeutic effectVSAvoidsafety concerns from gene introduction

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and utilizes the inherent immunomodulatory and regenerative potentials of stem cells without introducing foreign genes. By culturing and conditioning stem cells under specific conditions, their endogenous therapeutic functions are enhanced, avoiding the safety risks associated with genetic modification while maintaining therapeutic efficacy

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS20240052316A1Stem cell priming composition and primed stem cell

Publication Date: 2024.02.15 SCM LIFESCI CO LTD

AI summary

The present invention relates to a composition, comprising: TNF-α, IFN-γ, and IFN-α; or TNF-α, IFN-γ, IFN-α, and a vitamin, for enhancing immunomodulatory and inflammation-modulating ability of stem cells, and a method for preparing stem cells having improved immunomodulatory and inflammation-modulating ability by using same. Treatment of stem cells with: TNF-α, IFN-γ, and IFN-α; or TNF-α, IFN-γ, IFN-α, and a vitamin according to the present invention leads to upregulation of the expression of factors associated with the immunoregulatory activity and anti-inflammatory effects of stem cells and thus enables the preparation of functionally reinforced stem cells. The functionally reinforced stem cells thus prepared can find a wide spectrum of applications in various immune, inflammatory disease therapy fields.